PI3K p85 (alpha) antibody

Synonyms:GRB1 antibody, p85 antibody, p85 ALPHA antibody, PI 3 Kinase p85 alpha antibody, PI 3-kinase p85α antibody, PI3 kinase subunit p85 alpha antibody, PI3K p85(alpha) antibody, PI3K regulatory subunit alpha antibody, PIK3R1 antibody
Catalogue No.:FNab06422Reactivity:Human, Mouse, Rat
Host:MouseTested Application:ELISA, WB, IHC, IF, IP
Clonality:monoclonalIsotype:IgG1
  • SPECIFICATIONS
Product Name
PI3K p85 (alpha) antibody
Catalogue No.
FNab06422
Size
100μg
Form
liquid
Purification
Protein A+G purification
Purity
≥95% as determined by SDS-PAGE
Clonality
monoclonal
Isotype
IgG1
Clone ID
5G0
Storage
PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
Immunogen
Immunogen
phosphoinositide-3-kinase, regulatory subunit 1(alpha)
Alternative Names
GRB1 antibody, p85 antibody, p85 ALPHA antibody, PI 3 Kinase p85 alpha antibody, PI 3-kinase p85α antibody, PI3 kinase subunit p85 alpha antibody, PI3K p85(alpha) antibody, PI3K regulatory subunit alpha antibody, PIK3R1 antibody
UniProt ID
P27986
Observed MW
85 kDa
Application
Tested Applications
ELISA, WB, IHC, IF, IP
Recommended dilution
WB: 1:1000-1:10000; IP: 1:200-1:2000; IHC: 1:20-1:200; IF: 1:50-1:500
Validated Images
Neuro-2a cells were subjected to SDS PAGE followed by western blot with FNab06422(PIK3R1 Antibody) at dilution of 1:4000
IP Result of anti- PIK3R1 (IP: FNab06422, 5ug; Detection: FNab06422 1:500) with RAW 264.7 cells lysate 1480ug.
Immunohistochemistry of paraffin-embedded human prostate cancer slide using FNab06422(PIK3R1 Antibody) at dilution of 1:50
Immunofluorescent analysis of (-20℃ Ethanol ) fixed HeLa cells using FNab06422(PIK3R1 Antibody) at dilution of 1:100 and Alexa Fluor 488-conjugated Goat Anti-Mouse IgG(H+L)
Background
Phosphatidylinositol 3-kinase (PI3K) plays an important role in the metabolic actions of insulin and is required for adipogenesis. The PI3K pathway has also been identified as an important player in cancer development and progression. The Class IA PI3K heterodimer, which is composed of a P110 catalytic subunit and a P85 regulatory subunit, is activated upon association of the P85 subunit with upstream adaptor proteins or receptor tyrosine kinases. Mutations in PIK3R1 are implicated in cases of breast cancer and associated to SHORT syndrome.